Skip to main content
. 2017 Apr 3;7(4):e015365. doi: 10.1136/bmjopen-2016-015365

FigureĀ 1.

FigureĀ 1

Study design according to targeted objectives. BAT, best available therapy; CRE, carbapenem-resistant Enterobacteriaceae; CSE, carbapenem-susceptible Enterobacteriaceae.